AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
ERBB-2, P53, AND EFFICACY OF ADJUVANT THERAPY IN LYMPH NODE-POSITIVE BREAST-CANCER
Authors: THOR AD BERRY DA BUDMAN DR MUSS HB KUTE T HENDERSON IC BARCOS M CIRRINCIONE C EDGERTON S ALLRED C NORTON L LIU ET
Citation: Ad. Thor et al., ERBB-2, P53, AND EFFICACY OF ADJUVANT THERAPY IN LYMPH NODE-POSITIVE BREAST-CANCER, Journal of the National Cancer Institute, 90(18), 1998, pp. 1346-1360
DOSE AND DOSE INTENSITY AS DETERMINANTS OF OUTCOME IN THE ADJUVANT TREATMENT OF BREAST-CANCER
Authors: BUDMAN DR BERRY DA CIRRINCIONE CT HENDERSON IC WOOD WC WEISS RB FERREE CR MUSS HB GREEN MR NORTON L FREI E
Citation: Dr. Budman et al., DOSE AND DOSE INTENSITY AS DETERMINANTS OF OUTCOME IN THE ADJUVANT TREATMENT OF BREAST-CANCER, Journal of the National Cancer Institute, 90(16), 1998, pp. 1205-1211
IN-VITRO EVALUATION OF SYNERGISM OR ANTAGONISM WITH COMBINATIONS OF NEW CYTOTOXIC AGENTS
Authors: BUDMAN DR CALABRO A KREIS W
Citation: Dr. Budman et al., IN-VITRO EVALUATION OF SYNERGISM OR ANTAGONISM WITH COMBINATIONS OF NEW CYTOTOXIC AGENTS, Anti-cancer drugs, 9(8), 1998, pp. 697-702
PRELIMINARY STUDIES OF A NOVEL ORAL FLUOROPYRIMIDINE CARBAMATE - CAPECITABINE
Authors: BUDMAN DR MEROPOL NJ REIGNER B CREAVEN PJ LICHTMAN SM BERGHORN E BEHR J GORDON RJ OSTERWALDER B GRIFFIN T
Citation: Dr. Budman et al., PRELIMINARY STUDIES OF A NOVEL ORAL FLUOROPYRIMIDINE CARBAMATE - CAPECITABINE, Journal of clinical oncology, 16(5), 1998, pp. 1795-1802
CLINICAL CONFERENCE ON MANAGEMENT DILEMMAS - A YOUNG WOMAN WITH A 10-CM CHEST MASS
Authors: SMITH RM DUBINETT SM GRUDKO K ROSENOW EC BUDMAN DR SCHNADER J
Citation: Rm. Smith et al., CLINICAL CONFERENCE ON MANAGEMENT DILEMMAS - A YOUNG WOMAN WITH A 10-CM CHEST MASS, Chest, 114(1), 1998, pp. 295-306
DEVELOPMENT OF A FLUDARABINE PHOSPHATE (FAMP) DOSING FORMULA IN PATIENTS WITH RENAL-INSUFFICIENCY BASED ON A PHARMACOKINETIC (PK) STUDY IN PATIENTS WITH AND WITHOUT RENAL IMPAIRMENT
Authors: LICHTMAN SM CASACELLA P BUDMAN DR WILLIAMS G EISENBERG P DAMICO P OMARA V MUSGRAVE K ETCUBANAS E
Citation: Sm. Lichtman et al., DEVELOPMENT OF A FLUDARABINE PHOSPHATE (FAMP) DOSING FORMULA IN PATIENTS WITH RENAL-INSUFFICIENCY BASED ON A PHARMACOKINETIC (PK) STUDY IN PATIENTS WITH AND WITHOUT RENAL IMPAIRMENT, British Journal of Haematology, 102(1), 1998, pp. 245-245
ANDROGEN ANTAGONISTIC EFFECT OF ESTRAMUSTINE PHOSPHATE (EMP) METABOLITES ON WILD-TYPE AND MUTATED ANDROGEN RECEPTOR
Authors: WANG LG LIU XM KREIS W BUDMAN DR
Citation: Lg. Wang et al., ANDROGEN ANTAGONISTIC EFFECT OF ESTRAMUSTINE PHOSPHATE (EMP) METABOLITES ON WILD-TYPE AND MUTATED ANDROGEN RECEPTOR, Biochemical pharmacology, 55(9), 1998, pp. 1427-1433
SEVERE NEUROTOXICITY IN VINORELBINE-PACLITAXEL COMBINATIONS
Authors: BUDMAN DR WEISELBERG L OMARA V
Citation: Dr. Budman et al., SEVERE NEUROTOXICITY IN VINORELBINE-PACLITAXEL COMBINATIONS, Journal of the National Cancer Institute, 89(1), 1997, pp. 87-88
VINORELBINE (NAVELBINE(R)) - A THIRD-GENERATION VINCA ALKALOID
Authors: BUDMAN DR
Citation: Dr. Budman, VINORELBINE (NAVELBINE(R)) - A THIRD-GENERATION VINCA ALKALOID, Cancer investigation, 15(5), 1997, pp. 475-490
PHASE-II TRIAL OF DOCETAXEL IN NON-HODGKINS-LYMPHOMAS - A STUDY OF THE CANCER AND LEUKEMIA GROUP-B
Authors: BUDMAN DR PETRONI GR JOHNSON JL COOPER MR SCHLOSSMAN DM BARCOS M PETERSON BA
Citation: Dr. Budman et al., PHASE-II TRIAL OF DOCETAXEL IN NON-HODGKINS-LYMPHOMAS - A STUDY OF THE CANCER AND LEUKEMIA GROUP-B, Journal of clinical oncology, 15(10), 1997, pp. 3275-3279
DOWN-REGULATION OF PROSTATE-SPECIFIC ANTIGEN EXPRESSION BY FINASTERIDE THROUGH INHIBITION OF COMPLEX-FORMATION BETWEEN ANDROGEN RECEPTOR AND STEROID RECEPTOR-BINDING CONSENSUS IN THE PROMOTER OF THE PSA GENE IN LNCAP CELLS
Authors: WANG LG LIU XM KREIS W BUDMAN DR
Citation: Lg. Wang et al., DOWN-REGULATION OF PROSTATE-SPECIFIC ANTIGEN EXPRESSION BY FINASTERIDE THROUGH INHIBITION OF COMPLEX-FORMATION BETWEEN ANDROGEN RECEPTOR AND STEROID RECEPTOR-BINDING CONSENSUS IN THE PROMOTER OF THE PSA GENE IN LNCAP CELLS, Cancer research, 57(4), 1997, pp. 714-719
UNIQUE SYNERGISM OR ANTAGONISM OF COMBINATIONS OF CHEMOTHERAPEUTIC AND HORMONAL AGENTS IN HUMAN PROSTATE-CANCER CELL-LINES
Authors: KREIS W BUDMAN DR CALABRO A
Citation: W. Kreis et al., UNIQUE SYNERGISM OR ANTAGONISM OF COMBINATIONS OF CHEMOTHERAPEUTIC AND HORMONAL AGENTS IN HUMAN PROSTATE-CANCER CELL-LINES, British Journal of Urology, 79(2), 1997, pp. 196-202
COMPARISON OF CLINICAL COURSE OF CHRONIC LYMPHOCYTIC-LEUKEMIA PATIENTS BASED ON EXPRESSION OF SURFACE IMMUNOGLOBULINS
Authors: WASIL T ZUCKERMAN D BUCHBINDER A BUDMAN DR KOLITZ J LICHTMAN SM ALLEN SL SCHULMAN P VINCIGUERRA V CHIORAZZI N
Citation: T. Wasil et al., COMPARISON OF CLINICAL COURSE OF CHRONIC LYMPHOCYTIC-LEUKEMIA PATIENTS BASED ON EXPRESSION OF SURFACE IMMUNOGLOBULINS, Blood, 90(10), 1997, pp. 4116-4116
INVOLVEMENT OF PROSTATE-SPECIFIC ANTIGEN IN THE STIMULATION OF LNCAP CELL GROWTH
Authors: WANG LG LIU XM KREIS W BUDMAN DR
Citation: Lg. Wang et al., INVOLVEMENT OF PROSTATE-SPECIFIC ANTIGEN IN THE STIMULATION OF LNCAP CELL GROWTH, Oncology Reports, 3(5), 1996, pp. 911-917
CLINICAL PHARMACOKINETICS OF AMONAFIDE (NSC-308847) IN 62 PATIENTS
Authors: KREIS W CHAN K BUDMAN DR ALLEN SL FUSCO D MITTELMAN A FREEMAN J HOCK K AKERMAN S CALABRO A PUCCIO C SPIGELMAN M
Citation: W. Kreis et al., CLINICAL PHARMACOKINETICS OF AMONAFIDE (NSC-308847) IN 62 PATIENTS, Cancer investigation, 14(4), 1996, pp. 320-327
RELATIONSHIP BETWEEN TOXICITY AND OBESITY IN WOMEN RECEIVING ADJUVANTCHEMOTHERAPY FOR BREAST-CANCER - RESULTS FROM CANCER AND LEUKEMIA GROUP-B STUDY-8541
Authors: ROSNER GL HARGIS JB HOLLIS DR BUDMAN DR WEISS RB HENDERSON IC SCHILSKY RL
Citation: Gl. Rosner et al., RELATIONSHIP BETWEEN TOXICITY AND OBESITY IN WOMEN RECEIVING ADJUVANTCHEMOTHERAPY FOR BREAST-CANCER - RESULTS FROM CANCER AND LEUKEMIA GROUP-B STUDY-8541, Journal of clinical oncology, 14(11), 1996, pp. 3000-3008
PHARMACOKINETIC EVALUATION OF HIGH-DOSE ETOPOSIDE PHOSPHATE AFTER A 2-HOUR INFUSION IN PATIENTS WITH SOLID TUMORS
Authors: KREIS W BUDMAN DR VINCIGUERRA V HOCK K BAER J INGRAM R SCHACTER LP FIELDS SZ
Citation: W. Kreis et al., PHARMACOKINETIC EVALUATION OF HIGH-DOSE ETOPOSIDE PHOSPHATE AFTER A 2-HOUR INFUSION IN PATIENTS WITH SOLID TUMORS, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 378-384
PHASE-I STUDY OF HIGH-DOSE ETOPOSIDE PHOSPHATE IN MAN
Authors: FIELDS SZ BUDMAN DR YOUNG RR KREIS W INGRAM R SCHULMAN P CHERNY RC WRIGHT J BEHR J SNOW C SCHACTER LP
Citation: Sz. Fields et al., PHASE-I STUDY OF HIGH-DOSE ETOPOSIDE PHOSPHATE IN MAN, Bone marrow transplantation, 18(5), 1996, pp. 851-856
EARLY STUDIES OF ETOPOSIDE PHOSPHATE, A WATER-SOLUBLE PRODRUG
Authors: BUDMAN DR
Citation: Dr. Budman, EARLY STUDIES OF ETOPOSIDE PHOSPHATE, A WATER-SOLUBLE PRODRUG, Seminars in oncology, 23(6), 1996, pp. 8-14
NO INCREASED RISK OF TAXOL TOXICITY ZN OLDER PATIENTS
Authors: LICHTMAN SM ZAHEER W GAL D LOVECCHIO J DEMARCO LC SCHULMAN P BUDMAN DR TAIBBI R FENTON C VINCIGUERRA V
Citation: Sm. Lichtman et al., NO INCREASED RISK OF TAXOL TOXICITY ZN OLDER PATIENTS, Journal of the American Geriatrics Society, 44(4), 1996, pp. 472-474
PHARMACOKINETIC EVALUATION OF ZENIPLATIN IN HUMANS
Authors: DEMARCO LC BUDMAN DR LATHIA C AMORUSI P BIRKHOFER M LICHTMAN S WEISELBERG L VINCIGUERRA V LOVECCHIO J GAL D HOFFMAN A KANTROWITZ J RASTOGI R
Citation: Lc. Demarco et al., PHARMACOKINETIC EVALUATION OF ZENIPLATIN IN HUMANS, Cancer chemotherapy and pharmacology, 36(1), 1995, pp. 35-40
PHASE-I EVALUATION OF A WATER-SOLUBLE ETOPOSIDE PRODRUG, ETOPOSIDE PHOSPHATE, GIVEN AS A 5-MINUTE INFUSION ON DAY-1, DAY-3, AND DAY-5 IN PATIENTS WITH SOLID TUMORS
Authors: BUDMAN DR IGWEMEZIE LN KAUL S BEHR J LICHTMAN S SCHULMAN P VINCIGUERRA V ALLEN SL KOLITZ J HOCK K ONEILL K SCHACTER L BARBHAIYA RH
Citation: Dr. Budman et al., PHASE-I EVALUATION OF A WATER-SOLUBLE ETOPOSIDE PRODRUG, ETOPOSIDE PHOSPHATE, GIVEN AS A 5-MINUTE INFUSION ON DAY-1, DAY-3, AND DAY-5 IN PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 12(9), 1994, pp. 1902-1909
COMBINATION TRIAL OF SUBCUTANEOUS RECOMBINANT ALPHA-2B INTERFERON ANDORAL CYCLOPHOSPHAMIDE IN FOLLICULAR LOW-GRADE NON-HODGKINS-LYMPHOMA
Authors: OZER H ANDERSON JR PETERSON BA BUDMAN DR COOPER MR KENNEDY BJ SILVER RT HENDERSON ES DUGGAN DB BARCOS M BLOOMFIELD CD GOTTLIEB AJ
Citation: H. Ozer et al., COMBINATION TRIAL OF SUBCUTANEOUS RECOMBINANT ALPHA-2B INTERFERON ANDORAL CYCLOPHOSPHAMIDE IN FOLLICULAR LOW-GRADE NON-HODGKINS-LYMPHOMA, Medical and pediatric oncology, 22(4), 1994, pp. 228-235
DOSE AND DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY FOR STAGE-II, NODE-POSITIVE BREAST-CARCINOMA
Authors: WOOD WC BUDMAN DR KORZUN AH COOPER MR YOUNGER J HART RD MOORE A ELLERTON JA NORTON L FERREE CR BALLOW AC FREI E HENDERSON IC
Citation: Wc. Wood et al., DOSE AND DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY FOR STAGE-II, NODE-POSITIVE BREAST-CARCINOMA, The New England journal of medicine, 330(18), 1994, pp. 1253-1259
C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER
Authors: MUSS HB THOR AD BERRY DA KUTE T LIU ET KOERNER F CIRRINCIONE CT BUDMAN DR WOOD WC BARCOS M HENDERSON IC
Citation: Hb. Muss et al., C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER, The New England journal of medicine, 330(18), 1994, pp. 1260-1266
Risultati: 1-25 | 26-31